Spherix to conduct phase 3 clinical trial on Naturlose for type 2 diabetes

By Elaine Rigoli

Tampa, Fla., May 23 - Spherix, Inc. has signed an agreement with GleneaglesCRC Pte. Ltd. to conduct its phase 3 clinical trial on the use of Naturlose as a treatment for type 2 diabetes.

Gleneagles will conduct the main part of the trial in Australia, with patient recruitment slated to start by the end of 2006.

Spherix will contract with a separate contract research organization to conduct two smaller portions of the phase 3 trial covering other demographic groups in the United States, the company said in a news release.

Previous clinical trials show promise for Naturlose as a treatment for type 2 diabetes, the release said. These studies indicated that Naturlose can blunt the glucose spikes that occur after meals and thus may be useful in controlling certain symptoms of type 2 diabetes.

Located in Beltsville, Md., Spherix offers information technology, knowledge management and biotechnology.

GleneaglesCRC is a clinical research and drug-development company based in Singapore.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.